苯溴马隆的生物转化与鹰爪豆碱的多态性氧化无关。 - Suppr

Benzbromarone biotransformation is not related to polymorphic oxidation of sparteine.

作者信息

Walter-Sack I, Eichelbaum M, de Vries J X, Weber E

机构信息

Abteilung für Klinische Pharmakologie, Universität Heidelberg.

出版信息

Klin Wochenschr. 1988 Nov 1;66(21):1097-8. doi: 10.1007/BF01711926.

DOI:10.1007/BF01711926

PMID:3236759

Abstract

摘要

相似文献

Benzbromarone biotransformation is not related to polymorphic oxidation of sparteine.

Klin Wochenschr. 1988 Nov 1;66(21):1097-8. doi: 10.1007/BF01711926.

[The genetically determined polymorphism of metabolic oxidation of the sparteine-debrisoquin type].

Farmakol Toksikol. 1991 Nov-Dec;54(6):60-6.

[Clinical aspects of the polymorphism of oxidation phenotype].

Pol Tyg Lek. 1992;47(27-28):608-10.

S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population.

Br J Clin Pharmacol. 1994 Nov;38(5):463-5. doi: 10.1111/j.1365-2125.1994.tb04383.x.

The relationship between imipramine metabolism and the sparteine oxidation polymorphism.

Dan Med Bull. 1988 Oct;35(5):460-8.

The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide.

Clin Pharmacol Ther. 1989 May;45(5):562-7. doi: 10.1038/clpt.1989.73.

Polymerase chain reaction and its potential as a pharmacokinetic tool.

Clin Pharmacokinet. 1992 Nov;23(5):321-7. doi: 10.2165/00003088-199223050-00001.

Deficient benzbromarone elimination: a familial disorder?

Klin Wochenschr. 1990 Jan 19;68(2):101. doi: 10.1007/BF01646852.

Genetically determined sparteine oxidation polymorphism in a Polish population.

Eur J Clin Pharmacol. 1994;46(5):481-3. doi: 10.1007/BF00191917.

Polymorphic oxidation of debrisoquine and sparteine.

Prog Clin Biol Res. 1986;214:157-67.

引用本文的文献

Benzbromarone hydroxylation in man: defective formation of the 6-hydroxybenzbromarone metabolite.

Clin Investig. 1993 Nov;71(11):947-52. doi: 10.1007/BF00185609.

Variation of benzbromarone elimination in man--a population study.

Eur J Clin Pharmacol. 1990;39(2):173-6. doi: 10.1007/BF00280054.

Rapid and slow benzbromarone elimination phenotypes in man: benzbromarone and metabolite profiles.

Eur J Clin Pharmacol. 1990;39(6):577-81. doi: 10.1007/BF00316099.

本文引用的文献

Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Clin Pharmacol Ther. 1982 Feb;31(2):184-6. doi: 10.1038/clpt.1982.29.

Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Clin Pharmacokinet. 1982 Jan-Feb;7(1):1-22. doi: 10.2165/00003088-198207010-00001.

Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.

Br J Clin Pharmacol. 1983 Mar;15(3):317-21. doi: 10.1111/j.1365-2125.1983.tb01505.x.

[Genetic polymorphism of oxidative drug metabolism. Therapeutic and toxicologic implications].

Internist (Berl). 1983 Mar;24(3):117-27.

Analysis of benzbromarone in human plasma and urine by high-performance liquid chromatography and gas chromatography-mass spectrometry.

J Chromatogr. 1987 Jul 3;417(2):420-7. doi: 10.1016/0378-4347(87)80139-1.

Benzbromarone disposition and uricosuric action; evidence for hydroxilation instead of debromination to benzarone.

Klin Wochenschr. 1988 Feb 15;66(4):160-6. doi: 10.1007/BF01727785.

Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Nature. 1988 Feb 4;331(6155):442-6. doi: 10.1038/331442a0.

Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Drugs. 1985 Apr;29(4):342-75. doi: 10.2165/00003495-198529040-00003.

Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Eur J Clin Pharmacol. 1979 Sep;16(3):183-7. doi: 10.1007/BF00562059.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Benzbromarone biotransformation is not related to polymorphic oxidation of sparteine.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献